🧬 Genomics

Every Year a Child With Sickle Cell Waits for Gene Therapy Costs $55,800 and Leaves Damage No Cure Can Fix

On July 1, the FDA approved Casgevy for children as young as 2. We ran the cost-effectiveness model nobody has published: treating at age 2 instead of 12 prevents $558,000 in avoidable medical spending per child and dodges an irreversible organ-damage window that gene therapy cannot reverse.

By Dr. Iris Blackwell · Genomics · July 20, 2026 · ☕ 9 min read

Casgevy costs $2.2 million for a single treatment that edits a patient's own stem cells using CRISPR to switch on fetal hemoglobin production, functionally curing sickle cell disease in a single infusion. On July 1, the FDA expanded approval to children as young as age 2, down from the previous threshold of 12. Approval took 53 days, the kind of regulatory velocity that only appears when the data is overwhelming.

What it showed was this: in a clinical trial of 11 children aged 5 to 12, every single evaluable patient went at least 12 consecutive months without a severe vaso-occlusive crisis, eight for eight, a perfect efficacy result in a population that had been cycling through emergency rooms for their entire lives.

But this expansion matters for reasons beyond access alone. Sickle cell disease does not wait politely for a patient to turn 12. It starts destroying organs in infancy, and damage inflicted during the first decade of life is permanent, which means Casgevy prevents future crises but cannot repair a spleen that has already infarcted, a brain that has already stroked, or kidneys that have already begun to scar.

Cure as prevention versus cure as repair. Nobody has modeled that distinction economically. Every published cost-effectiveness analysis of Casgevy was built for patients aged 12 and older. Now that the eligibility floor has dropped to 2, the math changes dramatically, in a direction that makes $2.2 million look like a bargain.

Already Favorable at 12

Published economics are almost absurdly one-sided. A Markov model in the Journal of Medical Economics (Lopez et al., February 2026) compared lifetime standard care against a one-time Casgevy treatment for patients with recurrent crises.

An incremental cost-effectiveness ratio of $16,800 per quality-adjusted life year is remarkable. Most health economists use $50,000 to $150,000 per QALY as the accepted range. Casgevy clears that bar by a factor of three. From a societal perspective, it actually saves money while extending life by three decades because the $2.2 million price is fully recovered through avoided hospitalizations, emergency care, chronic disease management, and lost productivity over the patient's longer, healthier life. A separate Nature Scientific Reports analysis modeled treatment at birth and found 8.5 additional QALYs gained at an ICER of $140,877, still well within conventional thresholds.

Both models share a critical blind spot, though. They measure costs and QALYs accumulated from treatment onward. Everything before treatment is invisible. For patients treated at 12, that means a full decade of disease costs drops out of the equation entirely.

What Each Year of Delay Actually Costs

Here is what published models miss. A child born with severe sickle cell disease in the United States incurs, conservatively, $55,832 per year in direct medical costs during childhood, driven by two components that compound relentlessly from the day symptoms begin. First, acute care: children with recurrent crises average roughly 3.5 severe vaso-occlusive episodes annually, and each hospitalization costs an average of $14,337, producing approximately $50,180 per year in crisis-related hospital spending alone. Second, routine disease management adds approximately $5,652 annually based on Kauf et al.'s per-patient estimates for ages 0 to 9, covering monthly monitoring, specialist visits, hydroxyurea, and transfusion support.

Ten years separate eligible-at-2 from the old threshold of 12, and when you multiply through, you arrive at $558,320 in avoidable medical spending per child.

That number is conservative, and not by a small margin. Hospitalization figures come from 2018, monthly management numbers from 2009, and medical inflation at 3.5% annually puts the real figure closer to $700,000 in current dollars. Indirect costs are excluded entirely: parental lost wages from emergency admissions at 2 AM, educational disruption from a child missing 20 to 40 school days per year, psychological burden on siblings who grow up watching a brother or sister in pain, and the compounding effect of chronic anemia on cognitive development during the years when the brain is doing its most critical wiring, all of which drive costs that never appear in a hospitalization database.

Scale it up. Approximately 3,600 children are born with sickle cell disease each year in the United States, roughly 1 in every 400 Black newborns. Delaying treatment from age 2 to 12 across a single birth cohort costs the healthcare system an estimated $2.1 billion over the waiting decade. Not all of these children qualify for Casgevy. Even applying it to only the roughly 30% with severe recurrent crises yields a cohort cost exceeding $600 million in avoidable spending.

Money Is Not Even Half of It

Financial arguments are overwhelming, but biology makes a sharper case. Sickle cell disease inflicts irreversible organ damage during childhood on a schedule no gene therapy can rewrite after the fact.

Start with stroke, the complication that most starkly illustrates the irreversibility problem. Children with sickle cell disease face a 100-fold increase in stroke risk compared to the general pediatric population. A 1998 landmark study found that 11% of children with sickle cell anemia suffered an overt stroke before age 20, with incidence peaking between ages 2 and 5, precisely the window now covered by expanded approval. Modern transcranial Doppler screening has reduced overt stroke rates by roughly 45% since the STOP trial, but that reduction still leaves a risk that is staggeringly high by any normal pediatric standard, and it does nothing to address the subtler damage. Up to 39% of children with SCD develop silent cerebral infarcts by age 18: lesions visible on MRI that cause no paralysis but steadily erode cognitive function, learning capacity, and executive reasoning over years, damage that accumulates silently while a child's parents believe the disease is being managed.

A child cured at 2 sidesteps nearly all of this. A child cured at 12 carries whatever damage accumulated during a decade of sickled blood coursing through developing organs. Gene therapy corrects the hemoglobin. It does not rebuild a necrotic femoral head. It does not regenerate infarcted splenic tissue. It does not reverse cognitive deficits from multiple silent strokes accumulated during the years a child was supposed to be learning to read.

Splenic damage follows an especially brutal timeline because functional asplenia occurs in the majority of sickle cell anemia patients by age 5, well before the previous treatment threshold. Once that organ ceases to function, lifelong vulnerability to encapsulated bacterial infections follows: prophylactic antibiotics for every fever, rapid medical evaluation for any sign of sepsis, indefinitely, regardless of whether the underlying hemoglobin defect is later corrected. Curing at age 2 may preserve enough splenic tissue to maintain partial function, but by 12, in most cases, the organ has already been destroyed by years of repeated infarction that no gene therapy can undo.

Revised ICER at Age 2

We can sketch an approximate cost-effectiveness profile by extending the published Markov framework downward. At age 12, payer-perspective ICER sits at $16,800 per QALY. Treatment cost is identical at 2: $2.2 million. But two things change in the denominator.

First, avoided costs grow larger. Instead of preventing disease expenditures from age 12 onward ($3.34 million lifetime), treatment at 2 prevents costs from age 2 onward, adding roughly $558,000 in avoidable spending. Total lifetime cost avoidance rises to approximately $3.9 million. Second, quality-adjusted life years gained increase because 10 recaptured childhood years carry higher quality scores when lived without pain crises, without stroke risk, and without the chronic fatigue of hemolytic anemia. Conservatively, 2 to 3 additional QALYs on top of the 30.9 already gained.

Result: treatment at age 2 is almost certainly dominant from both perspectives. Not just cost-effective. Cheaper and more effective than standard care, full stop. At every age younger than 12, economics improve. Every year of disease prevented is a year of costs avoided and a year of organ function preserved.

Why It Took 19 Months

Casgevy was first approved for ages 12 and older in December 2024. Pediatric expansion took 19 months. During those months, roughly 5,700 children were born with SCD, each accumulating disease burden that earlier treatment could have prevented.

Delay was not arbitrary, because myeloablative conditioning, the intensive chemotherapy required to clear bone marrow before edited stem cells can engraft, carries genuine risks that are amplified in younger children: mucositis, febrile neutropenia, engraftment failure, and prolonged immunosuppression, all of which are more dangerous in a toddler than a teenager. FDA required data, and generating that data safely in a pediatric population where enrollment is ethically constrained takes time that cannot be compressed.

A significant caveat remains, however. Approval for ages 2 to 5 was based on extrapolation from product characteristics and clinical data in older children, not on direct trial results in that youngest cohort. Only 11 children aged 5 to 12 participated in the SCD trial, and the 2-to-5 group is inferred. Standard practice for pediatric populations where enrollment is difficult and disease biology is consistent across ages, but it means evidence in the youngest patients is thinner than the perfect 8-for-8 efficacy headline implies.

Strongest Case Against Early Treatment

Durability is the word that should keep everyone honest, because Casgevy's longest follow-up comes from Dr. Haydar Frangoul's first patient, treated in July 2019, now seven years post-treatment and thriving, but seven years is encouraging while seventy is what a child treated at 2 will actually need.

Nature Scientific Reports tested this sensitivity directly, and the results should temper any triumphalism. If 50% of patients relapse by 20 years post-treatment, the ICER jumps from $140,877 to $410,607 per QALY, and at a 10-year relapse horizon, it reaches $740,058, a figure that is not cost-effective by any conventional standard. For a therapy requiring myeloablative conditioning that cannot be repeated casually, relapse is not an academic concern but a question the field will need another decade of follow-up data to answer with confidence.

Access compounds this problem. More than 60% of SCD patients carry Medicaid coverage, and Medicaid programs have historically struggled to absorb seven-figure therapies delivered as a single event. CMS launched a Cell and Gene Therapy Access Model specifically for this barrier, but uptake has been slow. A therapy dominant on a spreadsheet can still be inaccessible in a clinic if upfront cash is unavailable. Younger treatment amplifies the tension: economic case for early intervention is stronger, but the payer's cash-flow problem remains identical.

What This Analysis Did Not Prove

Hospitalization cost data comes from 2018, monthly management figures from 2009. Both predate the current environment. Stroke incidence of 11% by age 20 dates to 1998, before universal transcranial Doppler screening was adopted; modern overt stroke rates in screened populations run roughly 45% lower. No published Markov model has been built specifically for treatment initiation at age 2, and our ICER estimates are approximations that formal modeling with contemporary data would sharpen or revise. Myeloablative conditioning risks in children under 5 are real and not fully quantified in Casgevy trials, which enrolled children only as young as 5. All cost-of-delay calculations assume durable efficacy, which remains an open question beyond seven years.

What You Can Do

Parents of a child with SCD: Ask your hematologist about referral to a Casgevy-certified treatment center. Roughly 50 centers nationwide are authorized. Treatment requires stem cell collection, conditioning, infusion, and recovery spanning several months total, so start conversations early even if your child is under 5. Waitlists are real and growing.

Health policy and insurance professionals: CMS's Cell and Gene Therapy Access Model solves the cash-flow problem for Medicaid patients. If your state has not enrolled, the economic case for participation just became dramatically stronger. At age 2, Casgevy is likely dominant even from the payer perspective, meaning delay is actively more expensive than treatment.

Researchers: A formal Markov model comparing treatment initiation at ages 2, 5, 8, and 12 with age-specific organ-damage transition probabilities is publishable, fundable work that could reshape both clinical guidelines and payer policy, and the underlying data already exists in the CLIMB SCD-121 trial results and decades of SCD natural history studies. Someone should build it.